Cell Therapy for Ischemic Stroke with Nanoparticle-Labeled 293T Cells and Bone Marrow-Derived Mesenchymal Stem Cells: A Feasibility Study.

On the corner test, the four-group analysis revealed a significant Group main effect (F(3,151) = 3.48, p = 0.034) with a highly significant Day effect (F(5,151) = 88.74, p < 0.001); the cumulative-burden AUC analysis confirmed this group difference (F(3,23) = 3.17, p = 0.046), and Tukey HSD post hoc indicated that rMSC-ION animals had significantly lower cumulative sensorimotor deficit than the published ischemic Control animals ( p = 0.040), whereas 293T-ION animals did not differ significantly from Control ( p = 0.254).

also in 132,142 other papers